SIMCERE PHARMA

Xiansheng Pharmaceutical Group Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is an innovative and research-driven pharmaceutical company with R&D, production and specialized marketing capabilities. The Group focuses on the fields of oncology, nervous system, autoimmunity and anti-infection, while actively proactively planning disease areas with major future clinical needs, and is committed to achieving the corporate mission of “enabling patients to use more effective drugs as soon as possible”. Within the focus area, the Group has seven innovative drugs approved for marketing. As of June 30, 2024, 14 products of the Group have entered the guidelines and routes published by more than 100 government agencies or authoritative professional societies, and more than 40 products have been included in the National Medical Insurance Drug Catalogue (“NRDL”). The Group attaches great importance to building innovative drug research and development capabilities. It has R&D innovation centers in Shanghai, Nanjing, Beijing, Boston and Hong Kong, as well as national key laboratories for neurological and oncology drug research and development. The Group's R&D system covers the entire process from drug discovery, pre-clinical development, clinical trials, and registration, and has leading platforms for protein engineering, multi-antibody/TCE, ADC, AI-assisted molecular generation, and protein degradation. As of June 30, 2024, the Group had about 880 R&D personnel (including 160 doctorates and 460 master's degrees). The Group has a nationwide marketing network and leading commercialization capabilities, and will continue to strengthen marketing specialization capabilities and improve drug coverage and accessibility. As of June 30, 2024, the Group's four major marketing divisions in Oncology, Neuroscience, Self-Relaxation, and Retail had a total of about 3,900 personnel across 32 provinces, cities and autonomous regions in China. The products covered more than 3,000 tertiary hospitals, about 17,000 other hospitals and medical institutions, and more than 200 large national or regional pharmacy chains across the country. The Group has built production facilities and quality management systems that meet international standards to continuously improve pharmaceutical production capacity. The six pharmaceutical production bases that have been put into use all meet China's GMP requirements, and some production lines have passed EU GMP certification or US Food and Drug Administration (“FDA”) inspection. Driven by independent research and collaborative innovation, the Group has established strategic partnerships with many innovative enterprises, research institutes, and clinical centers at home and abroad, exploring various collaborative models for cooperative research and development, transfer of results, etc., and continuously explores products that patients urgently need and have huge market potential. The Group has established a Scientific Advisory Board (SAB), bringing together more than a dozen world-leading scientists in the fields of oncology, nervous system, autoimmunity, etc., to use their professional abilities and industry experience to provide scientific advice for the Group's early drug discovery and clinical development, and explore and create unprecedented treatment methods.